Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa

The COVID-19 pandemic spreading had a major impact on our daily lives imposing worldwide healthcare providers to modify their methods of clinical practice. The COVID-19 vaccination is urgently needed to control the epidemic and return to normal life. To date, three different types of vaccines have been approved in Italy: two based on spike protein mRNA carried by lipidic microparticles and one based on spike protein mRNA carried by adenoviruses. The technology of these vaccines is different; this, combined with short development times and new technologies adopted, makes it necessary to collect real life efficacy and safety data. Hidradenitis suppurativa (HS) is a chronic relapsing skin inflammatory disease. The therapeutic management of HS is based on immunosuppressive therapies (steroids, dapsone, cyclosporine) or immunomodulatory therapies (antibiotics or biological drugs). The Hidradenitis Suppurativa Foundation from North America experts (HSF), based on real-life data and pathogenetic mechanisms of lethal COVID-19 cases, recommend to continue current biological treatment such as TNF-α, IL-12/IL-23 and IL-17 inhibitors suspending treatment only in case of COVID-19 suspicious symptoms. There are no recommendations to date regarding vaccination of HS subjects undergoing therapy because COVID vaccines are new and do not fall into any of the vaccine categories known so far.

Read more